Healthcare, Pharma & Life Sciences

Aurora Cannabis Reaffirms Q2 Growth Guidance on EU, UK Expansion

Image
Aurora Cannabis Reaffirms Q2 Growth Guidance on EU, UK Expansion

Edmonton – September 19, 2026 -- Aurora Cannabis Inc. (TSX: ACB) (NASDAQ: ACB) reaffirmed its fiscal 2027 second-quarter guidance for sequential growth in net revenue and adjusted EBITDA, citing new EU-GMP capacity and expanding market share in Germany, Poland and the United Kingdom.

Safari Flower Company adds EU-GMP capacity after July certification

The Canadian medical cannabis producer said its recently acquired Safari Flower Company, which received EU-GMP certification in July, is expected to generate incremental net revenue and adjusted EBITDA in the coming quarters. The certification adds to Aurora's position as one of the world's largest indoor EU-GMP certified producers.

45% of Facial Surgeons See Rise in Menopause-Linked Patient Requests

Image
45% of Facial Surgeons See Rise in Menopause-Linked Patient Requests

Washington – September 19, 2026 -- Forty-five percent of facial plastic surgeons report an increase in female patients citing menopause or perimenopause as a reason for seeking treatment, up sharply from 28% in 2024, according to the American Academy of Facial Plastic and Reconstructive Surgery's (AAFPRS) 2025 annual member survey.

Survey data shows a 17-point jump in menopause-related consultations year over year

The AAFPRS, representing more than 2,200 facial plastic and reconstructive surgeons worldwide, tracked the shift among its membership base as part of its annual industry survey. The increase indicates a growing willingness among patients to link hormonal transition directly to visible facial changes during consultations.

Nona Biosciences Debuts HCAbLM, First AI Model for Human HCAbs

Image
Nona Biosciences Debuts HCAbLM, First AI Model for Human HCAbs

Cambridge – September 19, 2026 -- Nona Biosciences has developed HCAbLM, the first language model trained specifically on fully human heavy-chain-only antibodies (HCAbs), built from a dataset of 31.8 million HCAb sequences drawn from 73 independently immunized transgenic mice. The findings were detailed in a study titled "A foundation model learns the sequence and functional grammar of fully human heavy-chain-only antibodies," published on bioRxiv.

Nona targets the developability bottleneck in AI antibody design

Current AI antibody discovery is limited less by target-binding design than by manufacturability at scale, aggregation risk and stability -- collectively known as developability. HCAbLM was built to learn the underlying sequence grammar that determines whether an HCAb can fold correctly and progress into a viable drug candidate. General-purpose protein models lack this capability because their training data contain almost no HCAb sequences.

New Study: 80% of Countries Fall Short of Dermatology Care Benchmark

Image
New Study: 80% of Countries Fall Short of Dermatology Care Benchmark

Global – September 19, 2026 -- More than two billion people worldwide live with skin disease, yet a new benchmark study finds over 80% of countries fall below the dermatologist density needed to meet demand, with 74% of nations reporting skin health is not a national government priority.

Global dermatologist density falls nearly half short of the new benchmark

The study, which supports implementation of the World Health Assembly's 2025 Resolution on Skin Diseases as a Global Public Health Priority, establishes the first evidence-based benchmark for adequate dermatology care. It finds a global average of 2.66 dermatologists per 100,000 people, against an estimated requirement of 5.63 per 100,000.

Brainomix Joins UK's Future Fifty Scale-Up Programme

Image
Brainomix Joins UK's Future Fifty Scale-Up Programme

Oxford – September 19, 2026 -- Brainomix, an Oxford-based AI-powered medical imaging company, has been selected to join Future Fifty, the UK's invitation-only scale-up programme run by Tech Nation and Founders Forum Group.

Brainomix joins 24 other companies in a cohort that has raised £1.47 billion collectively

The latest Future Fifty cohort spans 10 sectors including AI, healthtech, biotech, fintech, energy and advanced manufacturing, and employs more than 3,800 people across the group. The programme has previously supported 30% of all UK tech unicorns and 40% of the country's decacorns, including Revolut and Wise.

Lundbeck Wins Japan Approval for Migraine Drug Vyepti, First Solo Launch

Valby, Denmark – – September 19, 2026 -- H. Lundbeck A/S has secured marketing authorization from Japan's Ministry of Health, Labour and Welfare for eptinezumab, branded Vyepti, as a preventive treatment for migraine attacks in adults, opening the company's first independent product launch in the country.

MHLW clears the only IV CGRP-targeted migraine preventive on the market

Eptinezumab remains the sole intravenous CGRP-targeted therapy approved for migraine prevention, now available in more than 30 markets worldwide following the Japanese clearance. The drug was first approved by the U.S. FDA in February 2020, followed by the European Commission in January 2022 and, most recently, South Korea.

Rural Louisiana Hospital Featured in National PBS Healthcare Documentary

Image
Rural Louisiana Hospital Featured in National PBS Healthcare Documentary

New Orleans – September 19, 2026 -- West Ascension Parish Hospital Service District, a Critical Access Hospital serving Donaldsonville, Louisiana, has been selected for a national Public Television documentary segment examining rural healthcare delivery models, following on-location filming completed in July 2026.

Documentary segment examines how data tracking reshapes small-hospital operations

The feature on "All Access hosted by Andy Garcia" documents how the facility analyzes qualitative staff feedback alongside regional clinical outcomes to inform operational restructuring. The hospital tracks frontline workflow metrics to help physicians and nurses streamline patient handoffs and reduce procedural friction, using data gathered across multiple community touchpoints to build adaptable care models.

DentScribe Launches Benchmark Exposing AI Dental Note Accuracy Risks

Image
DentScribe Launches Benchmark Exposing AI Dental Note Accuracy Risks

Sunnyvale, Calif. – September 19, 2026 -- DentScribe, an AI platform for dental documentation, released Dental AI SOAP Note Benchmark 1.0 and a companion white paper titled "Beyond Transcription" to expose how AI-generated clinical notes can misrepresent patient care despite reading smoothly.

Benchmark tests whether AI scribes preserve clinical accuracy across ten focused cases

The benchmark includes ten focused test cases plus two source-based cases built from de-identified clinical excerpts that retain the original scattered order of a real chairside conversation, including interruptions, corrections, and unrelated asides. Test instructions require each AI product to process the same encounter with one standard request, with the first output compared against expected clinical content. A passing note must include every essential fact, contain no invented or conflicting clinical detail, and be organized for direct clinical use.

LGMD Advocates Press Congress for Rare-Disease Research Funding

Image
LGMD Advocates Press Congress for Rare-Disease Research Funding

Washington, D.C. – – September 19, 2026 -- Advocates for limb-girdle muscular dystrophy (LGMD) held more than 60 meetings with congressional offices this week, representing patients from over 20 states, as part of The Speak Foundation's LGMD Day on the Hill.

No FDA-approved treatment exists for LGMD despite scientific progress

LGMD is a group of rare genetic diseases causing progressive muscle weakness, and no FDA-approved treatment currently targets the condition. Advocates urged lawmakers to increase federal investment in LGMD research, expand access to Department of Defense research funding, and push for clearer, more consistent regulatory pathways for rare-disease treatments.

GHIT Fund Launches NTDpedia to Drive R&D Funding for 1.5 Billion People

Tokyo – September 19, 2026 -- The Global Health Innovative Technology (GHIT) Fund has launched NTDpedia, a digital encyclopedia targeting the awareness gap that keeps neglected tropical diseases (NTDs) underfunded despite affecting 1.5 billion people worldwide.

GHIT Fund targets awareness gap as root cause of NTD underfunding

The platform, titled "NTDpedia: Your Guide to Neglected Tropical Diseases," is designed as an accessible digital resource covering all 21 disease groups recognized by the World Health Organization, including viral, bacterial, parasitic, and fungal infections, snakebite envenoming, and noma. Supervised by Prof. Kenji Hirayama of Nagasaki University, the site aims to make complex health issues understandable to a general audience, including students, teachers, companies, and advocates.